Back to Network
11
Shared Docs
11
Same-Page
11 / 11
Mentions
Document Mentions (11 shared documents)
2 mentions1 same-page
Page ?Same page
pital to drive shareholder return. Next catalyst will be 2Q earnings/2/116 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning In generic pharma where s
n the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7.10y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, correlation has moved from around -80% a month ago to zero now. This means the volatility/leverage of risk panty port
2 mentions1 same-page
Page ?Same page
capital to drive shareholder return. Next catalyst will be 2Q eamings/2H16 Outlook on 8/8. AGN Is on our firm's US-1 list of best Investment Ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTCs approval of AGN generics deal. We continue to like TEVA's positioning In generic pharma where sc
n the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7.10y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, correlation has moved from around -80% a month ago to zero now. This means the volatility/leverage of risk parity por
2 mentions1 same-page
Page ?Same page
pital to drive shareholder return. Next catalyst will be 2Q earnings/V.116 Outlook on 8/8. AGN Is on our firm's US-1 list of best investment Ideas. Teva Pharma (TWA) - BAML reiterating BUY on TEVA after the FTCs approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where sca
n the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7.10y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, correlation has moved from around -80% a month ago to zero now. This means the volatility/leverage of risk parity por
Sponsored
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where
the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7-1=y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, =orrelation has moved from around -80% a month ago to zero now. This means the volatil=ty/leverage of risk parity po
2 mentions1 same-page
Page ?Same page
l to drive shareholder return. N=xt catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm :=17;s US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval=of AGN generics deal. We continue to like TEVA's positioning in generic=pharma where
the long term chart below and all time=high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7-1=y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, =orrelation has moved from around -80% a month ago to zero now. This means the volatility/leverage of risk parity po
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where
the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7-1=y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, =orrelation has moved from around -80%a month ago to zero now. This means the volatil=ty/leverage of risk parity por
Sponsored
2 mentions1 same-page
Page ?Same page
pital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7-10y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, correlation has moved from around -80% a month ago to zero now. This means the volatility/leverage of risk parity po
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7.10y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, correlation has moved from around -80% a month ago to zero now. This means the volatility/leverage of risk parity po
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7-10y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, correlation has moved from around -80% a month ago to zero now. This means the volatility/leverage of risk parity po
Sponsored
2 mentions1 same-page
Page ?Same page
apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where
the long term chart below and all time high in shares outstanding looks cheap. Chart One shows hourly data of IEF (7-1=y US Treasury ETF) and SPY (S&P500 ETF). Using 60 hourly data points, =orrelation has moved from around -80% a month ago to zero now. This means the volatil=ty/leverage of risk parity po
Sponsored
Mutual Connections (35)
Entities connected to both Teva Pharma and S&P500 ETF
Bloomberg L.P.
ORGANIZATION11 w/ Teva·11 w/ S&P500
Investment Grade ETF
ORGANIZATION11 w/ Teva·11 w/ S&P500
Paul Volcker
PERSON11 w/ Teva·11 w/ S&P500
Investment Grade Supply
ORGANIZATION11 w/ Teva·11 w/ S&P500
US Treasury ETF
ORGANIZATION11 w/ Teva·11 w/ S&P500
Jeffrey Epstein
PERSON11 w/ Teva·11 w/ S&P500
Richard Kahn
PERSON11 w/ Teva·11 w/ S&P500
Chart One
ORGANIZATION11 w/ Teva·11 w/ S&P500
HM
Hans Mikkelsen
PERSON11 w/ Teva·11 w/ S&P500
Frontier Communications
ORGANIZATION11 w/ Teva·11 w/ S&P500
Marc Rich
PERSON11 w/ Teva·11 w/ S&P500
Frontier Comm
ORGANIZATION10 w/ Teva·10 w/ S&P500
Spec Pharma
ORGANIZATION10 w/ Teva·10 w/ S&P500
Allergan
LOCATION9 w/ Teva·9 w/ S&P500
AM
Amanda
PERSON8 w/ Teva·8 w/ S&P500
AE
Amanda Ens
PERSON7 w/ Teva·7 w/ S&P500
PR
Pfd Return
PERSON7 w/ Teva·7 w/ S&P500
Bloomberg: Junk Debt Keeps Climbing Despite Plunging Oil Prices
ORGANIZATION6 w/ Teva·6 w/ S&P500
Non-Farm Payrolls
ORGANIZATION6 w/ Teva·6 w/ S&P500
Outlook
ORGANIZATION6 w/ Teva·6 w/ S&P500